Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IV
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancer
Conditions
Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Trial Timeline
May 19, 2016 → Dec 1, 2026
NCT ID
NCT02711553About Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IV
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IV is a phase 2 stage product being developed by Eli Lilly for Biliary Tract Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02711553. Target conditions include Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02711553 | Phase 2 | Active |
Competing Products
20 competing products in Biliary Tract Cancer